Drug Trial Radar · NCT03229200
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
297
Actual
Start
May 22, 2017
Primary completion
May 10, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- Pharmacyclics Switzerland GmbHAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Janssen Biotech, Inc., including Johnson & Johnson
- First posted
- Jul 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Conditions
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Leukemia, B-cell
- Graft Vs Host Disease
- Solid Tumor
Interventions
IbrutinibDrug
Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the drug safety profile by collecting long-term safety data for ibrutinib.Time frame: Up to 3 years and will be re-evaluated on an ongoing basis.
Locations
98 sites in 17 countries. Site status is shown where the registry gives one.
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center
Burbank, California
City Of Hope National Medical Center
Duarte, California
UCSD Moores Cancer Center
La Jolla, California
University of California Los Angeles (UCLA)
Los Angeles, California
Stanford University
Stanford, California
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Norton Medical Plaza II, 3991 Dutchmans Lane
Louisville, Kentucky
Dana-Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
TRIO - Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
John Theurer Cancer Center, Hackensack UMC
Hackensack, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Northwell Health
New Hyde Park, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medical College-New York Presbyterian Hospital
New York, New York
University of Rochester
Rochester, New York
Levine Cancer Institute
Charlotte, North Carolina
Southeastern Medical Oncology Center
Goldsboro, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center
Columbus, Ohio
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
M.D. Anderson Cancer Centre
Houston, Texas
US Oncology Research, LLC
The Woodlands, Texas
University of Vermont Medical Center
Burlington, Vermont
Swedish Cancer Institute
Seattle, Washington
Northwest Cancer Specialists, Compass Oncology
Vancouver, Washington
Wenatchee Valley Hospital and Clinics
Wenatchee, Washington
Yakima Valley Memorial Hospital
Yakima, Washington
St. George Hospital
Kogarah, New South Wales, Australia
Concord Repatriation General Hospital - Haematology Clinical Trials
Sydney, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Ballarat Health Services
Ballarat, Victoria, Australia
Eastern Health
Box Hill, Victoria, Australia
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.